Committed to bringing better, more effective new treatments to patients as quickly as possible, the MMRC is highly focused on spearheading Phase I and II clinical trials with associated correlative science studies. The MMRC also conducts pre-clinical validation studies to identify and prioritize the most promising novel compounds and combination therapies, and conducts genomics studies to develop a greater understanding of the biology of the multiple myeloma.
